Evidence map›Paper›PMID 40173337›Full record

ArticleThe CRISPR journal2025

Strategies for Interdisciplinary Human Gene Editing Research: Insights from a Swiss Project.

Agnes Kandlbinder, Marie-Hélène Peter-Spiess, Brigitte Leeners, Amina Mollaysa, Tommaso Cavazza, Anina Meier, Michael Braunschweig, Eleonora Ioannidi, Gerald Schwank, Michael Krauthammer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The CRISPR journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Agnes KandlbinderDepartment of Philosophy, Center for Ethics, Applied Ethics, University of Zurich, Zurich, Switzerland.ORCID 0009-0001-6850-6978
Marie-Hélène Peter-SpiessFaculty of Law, University of Zurich, Switzerland, and Global Health Centre (affiliated), Geneva Graduate Institute, Zurich, Switzerland.ORCID 0000-0003-0840-89003
Brigitte LeenersDepartment of Reproductive Endocrinology, University Hospital Zurich, Frauenklinikstr, Zurich, Switzerland.ORCID 0000-0003-4027-61514
Amina MollaysaDepartment of Quantitative Biomedicine, Medical informatics, University of Zurich, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0003-0547-13735
Tommaso CavazzaDepartment of Reproductive Endocrinology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland.ORCID 0000-0003-2544-53406
Anina MeierDepartment of Social Anthropology and Cultural Studies, Social and Cultural Anthropology, University of Zurich, Zurich, Switzerland.ORCID 0009-0004-0022-92757
Michael BraunschweigInstitute of Biomedical Ethics and History of Medicine, University of Zurich, Zurich, Switzerland.ORCID 0009-0001-9771-91158
Eleonora IoannidiInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0009-0008-3005-268410
Gerald SchwankInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-0767-2953
Michael KrauthammerDepartment of Quantitative Biomedicine, Medical informatics, University of Zurich, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-4808-1845

Funding

Swiss National Science Foundation 214936
6 · The paper itself

Abstract

CRISPR gene editing is a cutting-edge technology that has advanced tremendously in recent years. The first clinical CRISPR applications have been approved, and more gene editing therapies are to be expected in human medicine. Consequently, continuous basic research is needed to assess possibilities and prime future clinical applications. Because this technology not only offers new possibilities for treating diseases but also raises important ethical and societal questions, collaboration between human, life, biomedical, and medical sciences is needed. In this article, we discuss the practical challenges of such interdisciplinary projects and present strategies for addressing them based on our experience of conducting an interdisciplinary project on CRISPR. This work aims to help and encourage interdisciplinary collaborations and discussions on modern scientific endeavors that, such as gene editing, tend to blur the lines between traditional disciplines. The strategies suggested include realistic expectations, shared goals, space setting, and expert and lay dialogue.

Indexed as

Gene EditingInterdisciplinary ResearchCRISPR-Cas SystemsGenetic TherapyHumansSwitzerland

Identifiers

PMID40173337
PMCPMC7617730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.